teaser
The FDA has requested manufacturers of erythropoiesis-stimulating agents to add to the prescribing information for these drugs “black-box” warnings regarding a reduced survival rate when used in oncology patients.
↓Article continues below this sponsored advert↓
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
↑Advertisement↑
According to a Reuters Health News report, the warning will state that the drugs shortened overall survival, or caused more rapid tumour growth, in clinical studies in patients with breast, non-small-cell lung, head and neck, lymphoid and cervical cancers, when given at high doses.
